查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1801138

2025 年至 2033 年氣喘治療市場規模、佔有率、趨勢及預測（依藥物類別、產品類型、治療類型、給藥途徑及地區分類）

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球氣喘治療市場規模達188.3億美元。展望未來， IMARC Group估計，到2033年，市場規模將達到221億美元，2025年至2033年的複合年成長率為1.8%。目前，北美佔據市場主導地位，2024年的市佔率將超過50.0%。北美市場的成長得益於先進的醫療基礎設施、高氣喘盛行率、創新的治療方案以及強勁的研發投入。由於廣泛使用先進的生物製劑和聯合療法，加上有利於新產品核准的支持性監管框架，該地區在氣喘治療市場中佔有相當大的佔有率。

全球氣喘發病率不斷上升，這得益於空氣污染、過敏原、氣候變遷等環境因素以及遺傳因素，也催生了對更先進治療方案的需求。此外，生物製劑和合併用藥等新型療法的出現正在改變氣喘的治療。這些療法針對發炎和支氣管收縮，為中度至重度氣喘患者，尤其是對標準治療無效的患者，提供了更佳的療效和個人化治療方案。此外，先進生物製劑和聯合用藥的應用日益廣泛，尤其是在重度氣喘患者中，這為氣喘治療市場帶來了良好的前景。這些療法，包括單株抗體，提供了精準的治療方案，可顯著改善患者的治療效果。此外，政府機構和非政府組織 (NGO) 正在積極進行宣傳活動，宣傳早期發現和有效管理氣喘的重要性，鼓勵患者及時接受治療並遵循處方療法。

美國是市場中一個至關重要的細分市場，其驅動力源自於臨床試驗的成功，這些試驗證明了新型療法的有效性。積極的試驗結果通常會促成突破性療法的批准，從而滿足尚未滿足的醫療需求，尤其是在減少重度氣喘發作和改善長期管理方面。這些創新為療效樹立了新的標準。 2024年，阿斯特捷利康公佈了BATURA III期臨床試驗的積極結果，顯示其急救吸入器AIRSUPRA(R)（沙丁胺醇/布地奈德）顯著降低了間歇性或輕度持續性氣喘患者發生重度氣喘發作的可能性。由於療效顯著，該試驗被提前終止。 AIRSUPRA是美國首個獲準用於治療氣喘的抗發炎急救療法。

氣喘治療市場趨勢：

哮喘盛行率不斷上升

全球氣喘發病率不斷上升，尤其是在已開發和都市化地區，這是推動氣喘治療市場需求的重要因素。世界衛生組織 (WHO) 表示，2019 年全球共有 2.62 億人患有氣喘，導致 45.5 萬人死亡。空氣污染、過敏原和氣候變遷等環境因素，加上現代生活習慣，加劇了氣喘的流行，尤其是在高收入國家和快速城市化地區。疾病負擔的加重催生了對各種治療方案的需求，從傳統的吸入器到先進的生物製劑，再到輕度和重度氣喘患者的標靶治療。此外，對個人化醫療（針對特定個體的治療方法）的重視，已成為藥物研發創新的主要驅動力。隨著人們不斷努力減少氣喘患者的住院率並改善其生活品質，預計市場將進一步成長，這得益於持續的研究投入和全球醫療保健服務覆蓋率的改善。

治療方案的進展

創新性氣喘療法，尤其是生物製劑和標靶療法的開發，正在顯著推進治療方案的改進，並改善患者的預後。這些解決方案能夠減少氣道炎症，同時增強肺功能，使不同嚴重程度的氣喘患者的管理更加有效。此外，醫療保健提供者和患者對生物製劑透過提高療效和降低氣喘發作率所帶來的益處的認知不斷提高，也促使其被擴大採用。氣喘的高盛行率凸顯了這些療法的必要性。例如，根據美國疾病管制與預防中心2021年的報告，7.5%的5至11歲兒童患有氣喘。正在進行的研究項目，加上突破性藥物的監管授權，正在影響競爭環境，促進進步，並滿足全球氣喘患者尚未滿足的需求。

提高認知和早期診斷

人們對氣喘管理及早期發現的認知不斷提高，推動了氣喘治療市場的發展。隨著資訊和先進診斷設備的普及，人們的認知不斷提高，患者也越來越渴望及時治療，因此對正確治療的需求也越來越高。醫療機構和政府制定了教育計劃，加強對氣喘控制措施的教育，使其更注重定期檢查和後續治療。數位健康平台和智慧吸入器等技術的進步使患者能夠積極主動地進行疾病管理。隨著新產品的推出，市場上尚未滿足的醫療需求不斷被滿足。例如，2023年9月，歐盟批准了阿斯特捷利康的Tezspire（tezepelumab），用於治療12歲以上使用高劑量吸入皮質類固醇仍無法充分控制病情的重症氣喘患者。這些進展凸顯了創新和認知在支持氣喘治療市場成長中的作用。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球氣喘治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥品類別

  • 抗發炎藥物
  • 支氣管擴張劑
  • 聯合療法

第7章：市場區隔：依產品類型

  • 吸入器
    • 主要類型
      • 乾粉吸入器
      • 定量吸入器
      • 軟霧吸入器
  • 霧化器
    • 主要類型
      • 氣動霧化器
      • 超音波霧化器
      • 網狀霧化器

第8章：市場區隔：依治療類型

  • 快速緩解藥物
  • 長期氣喘控制藥物

第9章：市場細分：依行政途徑

  • 吸入
  • 口服
  • 腸外

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AstraZeneca PLC
    • Abbott Laboratories
    • Amgen Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck Sharp & Dohme Corp.
    • Novartis International AG
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2338

The global asthma therapeutics market size was valued at USD 18.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 22.1 Billion by 2033, exhibiting a CAGR of 1.8% from 2025-2033. North America currently dominates the market, holding a market share of over 50.0% in 2024. The growth of the North American market is driven by advanced healthcare infrastructure, high asthma prevalence, innovative treatment options, and strong investment in research and development. The region holds a significant asthma therapeutics market share because of the extensive use of advanced biologics and combination therapies, coupled with supportive regulatory frameworks that favor new product approvals.

The increasing incidence of asthma globally, linked to environmental influences like air pollution, allergens, and climate shifts, along with genetic factors, is creating a demand for more sophisticated treatments. Additionally, the emergence of new treatments, such as biologics and combination medications, is transforming asthma care. These therapies target inflammation and bronchoconstriction, providing enhanced effectiveness and customized options for moderate to severe instances, particularly for individuals who do not respond to standard treatments. Furthermore, the increasing utilization of sophisticated biologics and combination treatments, especially for severe asthma situations, is offering a favorable asthma therapeutics market outlook. These therapies, including monoclonal antibodies, provide precise options that greatly enhance patient results. In addition, government bodies and non-governmental organizations (NGOs) are vigorously running awareness initiatives regarding the significance of early detection and effective management of asthma, motivating patients to pursue prompt treatment and follow prescribed therapies.

The United States is a crucial segment in the market, driven by the success of clinical trials demonstrating the efficacy of novel treatments. Positive trial results often lead to the approval of groundbreaking therapies that address unmet medical needs, particularly in reducing severe exacerbations and improving long-term management. These innovations set new standards in treatment efficacy. In 2024, AstraZeneca reported favorable outcomes from the BATURA Phase III trial, indicating that its rescue inhaler AIRSUPRA(R) (albuterol/budesonide) considerably lowered the likelihood of severe asthma attacks in individuals with intermittent or mild persistent asthma. The trial was halted prematurely because of remarkable effectiveness. AIRSUPRA is the inaugural anti-inflammatory rescue treatment authorized in the US for managing asthma.

Asthma Therapeutics Market Trends:

Increasing Prevalence of Asthma

The rising incidence of asthma globally, particularly in developed and urbanized regions, is a significant factor driving the asthma therapeutics market demand. The World Health Organization (WHO) states that in 2019, 262 million individuals suffered from asthma, leading to 455,000 fatalities. Environmental factors such as air pollution, allergens, and climate changes, coupled with modern lifestyle habits, have intensified the prevalence of asthma, especially in high-income nations and rapidly urbanizing regions. Increased disease burden creates a need for a variety of treatments ranging from conventional inhalers to advanced biologics and targeted therapies treating both mild and severe asthma patients. Moreover, the emphasis on personalized medicine, treatment approaches aimed at specific individuals, has acted as a major driver of innovations in drug discovery. With continuous endeavors to reduce hospitalization and improve the quality of life for asthma patients, the market is only expected to grow further, supported by continued investments in research and improved healthcare access worldwide.

Advancements in Treatment Options

Development of innovative asthma therapeutics, particularly biologics and targeted therapies, is advancing treatment options significantly and improving patient outcomes. The solutions are reducing airway inflammation while enhancing lung function, making the management of asthma in patients with different levels of severity more effective. Additionally, the increase in awareness about the benefits of biologics by health care providers and patients through increased efficacy and decreased exacerbation rates has resulted in its increased adoption. The high prevalence of asthma highlights the necessity for these therapies. For instance, as per the 2021 report by the US Centers for Disease Control and Prevention, 7.5% of children between the ages of 5 and 11 experienced asthma. Ongoing research initiatives, coupled with regulatory authorizations for groundbreaking medications, are influencing a competitive environment, fostering progress, and addressing the unfulfilled requirements of asthma sufferers globally.

Increasing Awareness and Early Diagnosis

Rising awareness about the management of asthma and the early detection of asthma have driven the asthma therapeutics market. As the awareness has improved with the accessibility of information and advanced diagnostic equipment, the patient has been seeking timely treatment and therefore a high demand for proper treatments. Healthcare organizations and the government develop educational programs that increase education on asthma control measures, making it even more a periodic check and following up with given therapies. The advancement in technology through digital health platforms and smart inhalers is enabling patients to be proactive in disease management. With the launch of new products, unmet medical needs continue to get addressed in the market. For example, in September 2023, the European Union approved AstraZeneca's Tezspire (tezepelumab) for the treatment of severe asthma in patients aged 12 and older who are inadequately controlled with high-dose inhaled corticosteroids. These developments underline the role of innovation and awareness in supporting the asthma therapeutics market growth.

Asthma Therapeutics Industry Segmentation:

Analysis by Drug Class:

  • Anti-Inflammatory Drugs
  • Bronchodilators
  • Combination Therapies

Combination therapies lead the market because of their effectiveness in tackling various aspects of asthma management in one treatment. These treatments often merge inhaled corticosteroids (ICS) with long-acting beta-agonists (LABAs), providing anti-inflammatory advantages and prolonged bronchodilation. Their dual-action mechanism offers both instant relief from airway constriction and diminishes chronic inflammation, rendering them very effective for moderate to severe asthma instances. The ease of having one therapy improves patient adherence and streamlines treatment plans, especially for individuals with ongoing symptoms. Improvements in formulation technology have facilitated the creation of more focused and long-lasting combination treatments, enhancing clinical results and reducing side effects. Pharmaceutical companies are focusing on launching new products, like triple-combination therapies, to enhance treatment choices. Regulatory approvals and favorable clinical data have strengthened healthcare providers' confidence in these therapies, reinforcing their position as the favored option for thorough asthma management.

Analysis by Product Type:

  • Inhalers
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Soft Mist Inhalers
  • Nebulizers
    • Pneumatic Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Inhalers (dry powder inhalers, metered-dose inhalers, and soft mist inhalers), hold the biggest asthma therapeutics market share because of their extensive application and efficacy in directly administering medications to the lungs. Metered-dose inhalers are favored for their small size and accurate medication delivery, whereas dry powder inhalers provide user-friendliness without requiring propellants. Soft mist inhalers, featuring a fine mist and reliable dosing, serve patients who need a more gentle delivery method. The use of inhalers is motivated by their capacity for quick relief and sustained control, rendering them essential in the management of asthma. Innovations in technology, including smart inhalers equipped with digital tracking features, have improved treatment adherence and patient results. Furthermore, continuous advancements in formulation and device design are enhancing usability and effectiveness, making inhalers the preferred option for healthcare professionals and patients in asthma management.

Analysis by Treatment Type:

  • Quick-Relief Medications
  • Long-Term Asthma Control Medications

Long-term asthma control medications dominate the market due to their efficacy in controlling chronic asthma and decreasing both the occurrence and intensity of flare-ups. These drugs, such as inhaled corticosteroids, long-acting beta-agonists (LABAs), leukotriene modifiers, and biologics, aim to tackle the root inflammation and ensure stable lung performance over time. Their capacity to deliver reliable symptom control and enhance patients' quality of life establishes them as the foundation of asthma management approaches. Heightened awareness regarding the significance of consistent and preventive care has led to their common utilization. Improvements in biological treatments aimed at severe asthma cases, like monoclonal antibodies, have enhanced the segment's attractiveness by providing personalized and targeted solutions for patients not responding to conventional therapies. Pharmaceutical firms are actively funding research and development to launch novel combination medications and delivery systems, improving both effectiveness and patient compliance. Regulatory endorsements and broadened uses for biologics reinforce the sector's dominance in asthma treatments.

Analysis by Route of Administration:

  • Inhalation
  • Oral
  • Parenteral

Inhalers represent the largest segment, accounting 47.0% of the market share in 2024. Inhalation is the largest segment because it effectively administers medications straight to the lungs, providing quick symptom relief and improved treatment results. Inhaled treatments, such as corticosteroids, bronchodilators, and combination medications, are commonly favored for their targeted effects, which reduce systemic side effects relative to alternative methods of administration. The presence of different inhalation devices, including metered-dose inhalers, dry powder inhalers, and nebulizers, has enhanced patient compliance by providing choices suited to personal requirements. Advancements in technology, like smart inhalers equipped with digital tracking features, have increased the adoption of inhalation therapies by facilitating better asthma control through real-time monitoring of how medications are used. Regulatory approvals for novel formulations and the introduction of biosimilars in the inhalation sector have strengthened its dominance. Continual efforts by pharmaceutical companies to enhance the efficacy and convenience of inhaled medications strengthen their position as the primary choice for asthma treatment.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America held the largest market share, totaling 50.0%. North America dominates the market due to its strong healthcare infrastructure, significant research efforts, and widespread use of advanced medical technologies. The area gains from a significant presence of major pharmaceutical firms and solid regulatory structures that ease the approval and marketing of groundbreaking asthma therapies. Supportive healthcare policies and substantial government investment in respiratory disease research also enhance market expansion. Furthermore, the increasing incidence of asthma, influenced by environmental and genetic factors, has heightened the need for efficient treatment options. Furthermore, partnerships between academic institutions and industry stakeholders are driving the creation of innovative biologics and personalized medicine strategies, reinforcing North America's dominance in the asthma therapeutics sector. In 2024, Jasper Therapeutics announced that they have administered the first dose to a patient in the Phase 1b/2a ETESIAN clinical trial for briquilimab, a monoclonal antibody targeting c-Kit, designed for allergic asthma. The research will enroll 30 individuals from seven locations in Canada to evaluate the drug's efficacy, emphasizing mast cell reduction and respiratory response. The initial results are expected by the end of 2025.

Key Regional Takeaways:

United States Asthma Therapeutics Market Analysis

In North America, the United States represented 90.00% of the overall market share. In fact, the US asthma therapeutics market is growing with increased prevalence among people across different demographic categories. As highlighted by the CDC in 2020, almost 25 million people were estimated to be living with asthma in the U.S., further confirming the large number of affected populations. Also, adult women suffer disproportionately from asthma more than men do, indicating a need for individualized treatments for this demographic segment. More to this, children form a susceptible group, as per the Asthma and Allergy Foundation of America, where there are 5 million children asthmatic in the United States.

The high prevalence of asthma in adults and children is driving the demand for effective management strategies, including advanced inhalers, biologics, and combination therapies. Increased awareness about the importance of asthma control and early diagnosis has also encouraged more patients to seek medical intervention. These factors, coupled with ongoing innovation in asthma therapeutics, contribute to the expanding market in the United States, addressing the diverse needs of asthmatic patients across age groups.

Europe Asthma Therapeutics Market Analysis

The rising prevalence of asthma is fueling the asthma therapeutics market in Europe. Over 30 million adults and children are suffering from asthma in Europe, as has been reported by the European Lung Foundation, which clearly underlines the burden this chronic respiratory condition imposes. Women suffer more from asthma than men. This means there is a need for specific therapies that address the needs of this gender. Children, on the other hand, still form a susceptible population. The chronic illness, asthma, stands out as the most common condition among children in the region.

With the importance of early diagnosis and effective management surfacing awareness on advanced treatments such as biologics, combination therapies, and new inhalers, the overall need for this increase is coming out. Controlling asthma as proposed by national healthcare initiatives in Europe coupled with guidelines reinforces controlling asthma. Overall, along with the evolution in therapeutic options that are developing at a continued rate, asthma therapeutics demand will continue growing for all different groups of ages that suffer from it.

Asia Pacific Asthma Therapeutics Market Analysis

The Asia Pacific asthma therapeutics market is expanding fast, due to the increased incidence of asthma within the region. In China, asthma rates increased from 0.69% in 1984 to 5.30% in 2021, and it is estimated that they will rise up to 9.76% by 2050, according to BMC Public Health. The sharp increase indicates a great demand for the management of asthma in one of the region's largest populations. India also has a significant asthma burden. According to the NIH, 34.3 million cases of asthma have been reported in India, accounting for 13.09% of the global disease burden.

With prevalence continuously on the rise, asthma is a strongly developing market, in terms of need for advance therapy, in form of biologics and combination therapies. It is supplemented with next generation inhalers also. Greater emphasis towards early stage diagnosis and subsequent treatment has ensured their adoption, not to speak of government sponsored health care provisions and an up rising middle class looking forward to enhance access to care. All such factors together placed Asia Pacific region at the highest.

Latin America Asthma Therapeutics Market Analysis

The Latin America asthma therapeutics market is currently witnessing healthy growth due to a high and continuously rising prevalence of asthma in the region. Data published by industry reports in 2023 indicates that the overall prevalence of asthma in Latin America is about 17%, and the rates go up to as high as 30% in countries like Costa Rica. Thus, this area reflects a major unmet need for asthma management solutions appropriately addressed to the heterogeneous populations of the region.

With increased awareness of asthma as a chronic condition and its impact on quality of life, the demand for advanced therapeutics, such as inhalers, biologics, and combination therapies, has been increasing. Improved healthcare infrastructure and access to medical facilities in many Latin American countries further support the adoption of these therapies. The importance of early diagnosis and preventive care by governments and healthcare providers are significant factors that can mitigate asthma. Together, these aspects make the asthma therapeutic market in Latin America continue to grow.

Middle East and Africa Asthma Therapeutics Market Analysis

The asthma therapeutics market in the Middle East and Africa (MEA) is experiencing significant growth because of the high incidence of asthma and severe asthma in many nations throughout the region. According to industry reports, severe asthma rates are significantly high in African nations, with Kenya and Uganda showing 27% and Ethiopia at 19.9%. These statistics have created a significant burden of asthma-related health issues in the area, raising the need for efficient asthma management strategies.

Greater awareness of asthma as a chronic disease, coupled with better access to healthcare facilities, is driving adoption of advanced therapeutic options, such as inhalers, biologics, and targeted therapies. In addition, the increased interest in early diagnosis and personalized treatment plans, especially in urbanized regions, has helped manage asthma better. Such factors, coupled with the upgrading of healthcare infrastructure and government policies, are supporting the growth of the asthma therapeutics market in the Middle East and Africa.

Competitive Landscape:

Major market participants are concentrating on innovation, strategic alliances, and geographic growth to strengthen their market presence. They are making significant investments in research and development to launch advanced biologics and combination therapies that enhance efficacy and patient adherence. Businesses are also utilizing digital health technologies, like smart inhalers and mobile apps, to better monitor and manage asthma symptoms. Regulatory authorizations for new formulations and biosimilars are being sought to enhance product portfolios. Collaborative alliances with academic institutions and biotech firms are aiding in the discovery of new therapeutic approaches. In 2024, Teva Pharmaceuticals announced a clinical collaboration with Abingworth, securing as much as $150M in funding to advance TEV-248, a late-stage asthma rescue inhaler that combines ICS/SABA for adult and pediatric patients. Launch Therapeutics will carry out clinical trials, while Teva will focus on production and marketing. This aligns with Teva's "Pivot to Growth" strategy, emphasizing the pipeline's expansion.

The report provides a comprehensive analysis of the competitive landscape in the asthma therapeutics market with detailed profiles of all major companies, including:

  • AstraZeneca PLC
  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Novartis International AG
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the asthma therapeutics market?
  • 2.What is the future outlook of asthma therapeutics market?
  • 3.What are the key factors driving the asthma therapeutics market?
  • 4.Which region accounts for the largest asthma therapeutics market share?
  • 5.Which are the leading companies in the global asthma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Anti-Inflammatory Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Combination Therapies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Inhalers
    • 7.1.1 Market Trends
    • 7.1.2 Major Types
      • 7.1.2.1 Dry Powder Inhalers
      • 7.1.2.2 Metered Dose Inhalers
      • 7.1.2.3 Soft Mist Inhalers
    • 7.1.3 Market Forecast
  • 7.2 Nebulizers
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Pneumatic Nebulizers
      • 7.2.2.2 Ultrasonic Nebulizers
      • 7.2.2.3 Mesh Nebulizers
    • 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

  • 8.1 Quick-Relief Medications
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Long-Term Asthma Control Medications
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Inhalation
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Parenteral
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AstraZeneca PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Abbott Laboratories
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Boehringer Ingelheim International GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck Sharp & Dohme Corp.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis International AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sunovion Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Asthma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Asthma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Asthma Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Asthma Therapeutics Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Asthma Therapeutics Market: Breakup by Treatment Type (in %), 2024
  • Figure 6: Global: Asthma Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Asthma Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Asthma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Asthma Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Asthma Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Asthma Therapeutics (Combination Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Asthma Therapeutics (Combination Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Asthma Therapeutics (Inhalers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Asthma Therapeutics (Inhalers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Asthma Therapeutics (Nebulizers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Asthma Therapeutics (Nebulizers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Asthma Therapeutics (Quick-Relief Medications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Asthma Therapeutics (Quick-Relief Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Asthma Therapeutics (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Asthma Therapeutics (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Asthma Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Asthma Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Asthma Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Asthma Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia Pacific: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia Pacific: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Asthma Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Asthma Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Asthma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Asthma Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Asthma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Asthma Therapeutics Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 4: Global: Asthma Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 5: Global: Asthma Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Asthma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Asthma Therapeutics Market Structure
  • Table 8: Global: Asthma Therapeutics Market: Key Players